Anika Therapeutics (ANIK) Raw Materials (2011 - 2018)

Anika Therapeutics (ANIK) has reported Raw Materials for 8 consecutive years, with $13.2 million the latest figure, recorded in Q3 2018.

• On a quarterly basis, Raw Materials rose 68.31% year-over-year to $13.2 million in Q3 2018; TTM through Sep 2018 was $13.2 million, a 68.31% increase from a year earlier, with the FY2017 full-year figure at $11.3 million, up 91.98% from the prior year.
• Raw Materials was $13.2 million for Q3 2018 at Anika Therapeutics, up from $12.6 million in the prior quarter.
• Over five years, Raw Materials peaked at $13.2 million in Q3 2018 and troughed at $4.9 million in Q3 2015.
• A 5-year average of $7.4 million and a median of $6.3 million in 2017 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials slipped 28.96% in 2015 and jumped 100.13% in 2018, its largest moves.
• Over 5 years, Raw Materials stood at $6.2 million in 2014, then slipped by 6.2% to $5.8 million in 2015, then rose by 1.8% to $5.9 million in 2016, then surged by 91.98% to $11.3 million in 2017, then grew by 17.22% to $13.2 million in 2018.
• The last three Raw Materials figures came in at $13.2 million (Q3 2018), $12.6 million (Q2 2018), and $10.1 million (Q1 2018), per Business Quant data.